Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and psychological disorders:

Search results

Items: 1 to 20 of 281

1.

Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder.

Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Edden RAE, Williams S, Murphy DGM, Daly E, McAlonan GM.

Neuropsychopharmacology. 2019 Feb 6. doi: 10.1038/s41386-019-0333-8. [Epub ahead of print]

PMID:
30758329
2.

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.

Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J.

Alcohol Clin Exp Res. 2019 Jan 30. doi: 10.1111/acer.13964. [Epub ahead of print] Review.

PMID:
30698831
3.

Cannabis and Mood Disorders.

Lucatch AM, Coles AS, Hill KP, George TP.

Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10.

PMID:
30643708
4.

Effects of cannabidiol in males and females in two different rat models of depression.

Shbiro L, Hen-Shoval D, Hazut N, Rapps K, Dar S, Zalsman G, Mechoulam R, Weller A, Shoval G.

Physiol Behav. 2019 Mar 15;201:59-63. doi: 10.1016/j.physbeh.2018.12.019. Epub 2018 Dec 17.

PMID:
30571957
5.

Unique treatment potential of cannabidiol for the prevention of relapse to drug use.

Weiss F, Gonzalez-Cuevas G.

Neuropsychopharmacology. 2019 Jan;44(1):229. doi: 10.1038/s41386-018-0218-2. No abstract available.

PMID:
30254292
6.

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.

Poleg S, Golubchik P, Offen D, Weizman A.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:90-96. doi: 10.1016/j.pnpbp.2018.08.030. Epub 2018 Aug 29. Review.

PMID:
30171992
7.

Cannabis in liver disorders: a friend or a foe?

Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R.

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1283-1290. doi: 10.1097/MEG.0000000000001256. Review.

PMID:
30169449
8.

Cannabinoid concentrations in blood and urine after smoking cannabidiol joints.

Meier U, Dussy F, Scheurer E, Mercer-Chalmers-Bender K, Hangartner S.

Forensic Sci Int. 2018 Oct;291:62-67. doi: 10.1016/j.forsciint.2018.08.009. Epub 2018 Aug 11.

PMID:
30149280
9.

[A brief history of marijuana in the western world].

Leal-Galicia P, Betancourt D, Gonzalez-Gonzalez A, Romo-Parra H.

Rev Neurol. 2018 Aug 16;67(4):133-140. Review. Spanish.

PMID:
30039841
10.

Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity.

Grimm O, Löffler M, Kamping S, Hartmann A, Rohleder C, Leweke M, Flor H.

Eur Neuropsychopharmacol. 2018 Jul;28(7):841-849. doi: 10.1016/j.euroneuro.2018.04.004. Epub 2018 Jun 7.

PMID:
29887287
11.

[Current and future pharmacotherapy of severe psychiatric disorders].

Češková E.

Cas Lek Cesk. 2018 Spring;157(2):96-100. Czech.

PMID:
29790360
12.

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P.

Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. doi: 10.1017/S2045796018000239. Epub 2018 May 23. Review.

PMID:
29789034
13.

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.

Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group.

BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2.

14.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

15.

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.

Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Yücel M, Solowij N.

Cannabis Cannabinoid Res. 2018 Apr 1;3(1):94-107. doi: 10.1089/can.2017.0047. eCollection 2018.

16.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M.

Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.

PMID:
29619533
17.

Novel treatment options in depression and psychosis.

Ceskova E, Silhan P.

Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747. doi: 10.2147/NDT.S157475. eCollection 2018. Review.

18.

Police probe of Brazilian marijuana researcher sparks protests.

Angelo C.

Nature. 2018 Mar 15;555(7696):296. doi: 10.1038/d41586-018-02842-0. No abstract available.

PMID:
29542710
19.

Cannabis-based medicines for chronic neuropathic pain in adults.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W.

Cochrane Database Syst Rev. 2018 Mar 7;3:CD012182. doi: 10.1002/14651858.CD012182.pub2. Review.

PMID:
29513392
20.

Clinical Challenges in the Growing Medical Marijuana Field.

Barker J.

R I Med J (2013). 2018 Mar 1;101(2):12-13.

PMID:
29490316

Supplemental Content

Loading ...
Support Center